{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-241705","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.362393+00:00","generated_at":"2026-05-17T03:24:54.428386+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M","bullets":["CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.","Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.","Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.","OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.","Departure not due to any disagreement with the company on operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-241705","json":"https://secwatch.observer/filing/0001193125-25-241705.json","markdown":"https://secwatch.observer/filing/0001193125-25-241705.md","text":"https://secwatch.observer/filing/0001193125-25-241705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/0001193125-25-241705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/rcel-20251016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:24:54.428386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}